CFTR and liver disorder: Barriers such as advanced liver disease, adverse hepatic events, and economic constraints impede the equitable availability of CFTR modulators, demanding a comprehensive understanding of their safety profiles to identify patients at the highest risk of serious adverse events and achieve optimal risk–benefit ratios [69].